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Purpose/Objective: It has been demonstrated that non-
adherence to protocol-specified radiotherapy (RT) 
requirements is associated with reduced survival, local 
control and potentially increased toxicity [1]. Thus, quality 
assurance (QA) of RT is important when evaluating the results 
of clinical trials. RT-QA of large multicentre-trials, however, 
requires substantial effort and resources. Recently, we 
presented a digital QA platform, the CIRRO dose plan bank, 
which allows for central review of such trials. Here, we 
present our RT-QA results from the latest completed clinical 
protocol from the Danish Head and Neck Cancer Group 
(DAHANCA). 
Materials and Methods: The clinical results of the DAHANCA 
19 randomized phase III trial evaluated the effect of 
concurrent EGFR-inhibition during primary curative (chemo) 
radiotherapy in patients with head and neck squamous cell 
carcinoma (HNSCC). A total of 504 Danish patients entered 
the protocol in 2007-2012. Patients received RT at 5 different 
oncology centers to a total dose of 66-68Gy, 2Gy/fx, 6 
fx/week. For the current QA analysis, total treatment time, 
CTV coverage, and near-max doses to the spinal cord and 
brainstem including the corresponding planning risk volumes 
(PRVs) were evaluated according to 2004 DAHANCA 
guidelines. Each QA parameter was scored within three 
categories: 1) Full compliance to protocol guidelines, 2) 
Minor deviations: Not according to guidelines, but without 
clinical relevance, and 3) Major deviations: Clinical 
significant deviation. Categories 1) and 2) are clinical 
acceptable, whereas category 3) is clinical unacceptable. 
Results: The complete digital RT dataset was uploaded for all 
504 patients and QA parameters were extracted. The results 
are shown in table 1. Not all patients contribute to the PRV 
data, since the PRV concept was introduced in the Danish 
clinics shortly after 2007. Furthermore, 13 patients (2.6%) 
were eliminated from the CTV QA due to challenges to 
extract dose summations (e.g. re-scans and primary/ boost 
dose plans) from the database. A total of 11 major deviations 
were recorded. Four major deviations in CTV1 dose coverage 
were due to clinical considerations of the tolerance dose to 
the spinal cord, thus compromising target dose. Five of the 
major deviations in total treatment time were related to co-
morbidities, such as alcohol- or cardiac related matters and 
hospitalization. The remaining two cases were due to 
tracheotomy procedures and subsequent re-scans, which 
delayed the RT course. 
 
 
Table 1: Summary of results from RT-QA of the DAHANCA 
protocol. 
 
Conclusions: RT dose plans in DAHANCA 19 adhere well to 
national clinical guidelines. A total of 11 major deviations 
were found in 504 patients. All majors were clinically well 
accounted for. 
[1] D. C. Weber et al.: 'QA makes a clinical trial stronger: 
Evidence-based medicine in radiation therapy', Radiother. 
Oncol. 105 (2012) 4-8. 
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Purpose/Objective: During lung cancer radiotherapy, 
anatomical changes are frequently observed on cone-beam 
CT scans used for position verification and adaptive 
replanning might be needed without prolongation of overall 
treatment time. A method for fast re-evaluation of the dose 
distribution on small FOV CBCTs was developed. The 
influence of anatomical changes on the dose distribution was 
evaluated in a group of lung cancer patients. 
Materials and Methods: In 13 lung cancer cases a CBCT 
(Elekta XVI) and a repeat planning CT (Philips Brilliance) were 
obtained on the same day to ensure identical anatomy. The 
CBCT was registered on the repeat CT, which in turn was 
registered to the original planning CT according to the 
clinically applied patient shift. The original treatment plan 
and delineated structures were transferred to the repeat CT 
and CBCT to recalculate the dose. Dose calculation on the 
CBCT was done in Pinnacle3 v9.6 (Philips) by (1) adding the 
remainder of the body contour missing on the CBCT by taking 
the body contour of the planning CT with a density override 
equal to one; (2) Overriding the density of the CBCT outside 
the patient to 0; (3) Deriving a patient-specific HU-to-density 
table by comparing CT values of corresponding points on the 
CBCT and original planning CT; (4) Recalculating the dose 
using the individualised HU-to-density table and a standard 
table for XVI lung scans. Clinically relevant dose parameters 
were compared to assess the accuracy of this approach. The 
impact of anatomical changes on the dose distribution was 
evaluated. 
Results: In all clinical cases the CBCT could be successfully 
registered on the repeat CT, and only minor differences in 
the anatomy were visible. A complete dose evaluation could 
be performed in ~ 10 minutes. GTV and PTV coverage, the 
dose to the lungs (V20Gy, MLD), oesophagus (mean dose, V35Gy), 
spinal cord (max dose) and heart (mean dose) were scored 
for the repeat CT and CBCT dose calculation. Figure 1 
displays the average and standard deviation (error bars) of 
the absolute relative difference of the dose metrics between 
repeat CT and CBCT, both using a standard HU-to-density 
table for the CBCT lung XVI protocol, as well as a patient-
specific table. A good agreement between the dose 
distributions recalculated on CBCT and repeat CT was 
observed for most patients when a patient-specific HU-to-
density table was used.  
Compared to the planning CT, the observed dose differences 
did not necessitate plan adaptation in 10 of the 13 cases, as 
the target coverage was sufficient and tolerance levels of the 
OARs were not exceeded. Three cases with tumour shifts 
leading to an insufficient coverage of the target were 
replanned. 





Conclusions: A fast re-evaluation of the dose distribution 
using small FOV CBCT data is feasible in lung cancer patients. 
The use of patient-specific HU-to-density tables significantly 
improves the accuracy of these dose calculations. Only three 
of the 13 patients needed to be replanned to ensure 
sufficient target coverage.  
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Purpose/Objective: To quantify the influence of different 
IGRT alignment techniques on geometrical and dosimetrical 
consequences for proton irradiation of prostate cancer under 
consideration of actual occurring interfractional changes in a 
prospective patient positioning study. 
Materials and Methods: Ten prostate cancer patients, 
treated with photons, were positioned according to an in-
house protocol for proton therapy including the application of 
water-filled rectum balloons. A series of computed 
tomography data with 10-18 (median 15) in-room control CT 
scans per patient was acquired on different treatment days 
during the 8 week treatment for IGRT. Initial proton therapy 
plans were generated on the pre-treatment CT using passive 
field formation with two lateral fields. Planning was done on 
the CTV taking into account beam delivery uncertainties in 
the field-specific hardware. For evaluation purposes a PTV 
was created (CTV+5 mm/4 mm dorsal). Based on the control 
CTs, two different patient alignment approaches were 
simulated using rigid image registration: (a) Matching of the 
pelvic bony anatomy (BAM) and (b) Matching based on 
implanted marker seeds (MSM). For both approaches, the 
dose distribution per fraction and the accumulated dose 
distribution were evaluated. For dose accumulation non-rigid 
deformable image registration of the control CTs with the 
planning CT was applied. 
Results: The preliminary evaluation (7 of the 10 patients) 
revealed in general an advantage of the bony anatomy 
matching concerning target coverage. In all patients BAM 
target coverage was either better or similar compared to 
MSM. Aligning based on the bony anatomy (BAM) resulted in a 
mean displacement of the CTV center of 0.5 mm, -1.2 mm 
and -2.3 mm in the LR-, AP- and SI-direction, respectively. 
The mean Euclidean shift was 3.4 mm, hence substantially 
smaller than the CTV-PTV margin of 5 mm and comparable to 
MSM (3.0 mm). Based on the control CTs, on average only 2 
ml of the CTV (<2%) were outside of the original PTV for both 
BAM and MSM. Dosimetric evaluation of the accumulated dose 
distributions revealed a reduction of the CTV V95% relative to 
the planning CT of 1.6% and 2.1% for BAM and MSM, 
respectively. Analogously, the PTV V90% was reduced by 3.2% 
(BAM) and 4.5% (MSM). Moreover, for MSM the CTV minimum 
dose was reduced to a larger extent compared to BAM (on 
average -20% vs. -14%). The mean dose for rectum and 
bladder changed relative to the initial treatment plan on 
average by 12.1% and -15.2% for BAM and 9.5% and -4.9% for 




Conclusions: From the preliminary results it can be 
concluded that for proton therapy patient positioning based 
on bony anatomy is altogether superior to the marker 
matching leading to adequate dose distributions for both 
target and organs at risks. The applied uncertainty margins 
